mRNA vaccines open the field for a safety-optimized prophylactic vaccination in opposition to allergic diseases. Conventional as well as self-replicating mRNA vaccines have proven their capability to prevent the induction of an allergic phenotype in terms of allergen-specific IgE, allergy-related cytokine profiles, eosinophilic lung infiltration, and airway hyperreactivity. Along with wide range of services in the field of theraupetic development, Seattle Genova also offer services for mRNA merchandise used against allergies.